MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.18
-0.13
-1.56%
After Hours: 8.18 0 0.00% 16:00 04/16 EDT
OPEN
8.31
PREV CLOSE
8.31
HIGH
8.31
LOW
7.96
VOLUME
350.73K
TURNOVER
--
52 WEEK HIGH
11.57
52 WEEK LOW
1.370
MARKET CAP
700.86M
P/E (TTM)
-11.6907
1D
5D
1M
3M
1Y
5Y
JonesTrading Keeps Their Buy Rating on Chimerix (CMRX)
SmarterAnalyst · 6d ago
Chimerix Stock Gives Every Indication Of Being Significantly Overvalued
GuruFocus News · 04/09 21:51
Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the Ameri...
GlobeNewswire · 04/08 21:01
What Kind Of Shareholders Hold The Majority In Chimerix, Inc.'s (NASDAQ:CMRX) Shares?
Simply Wall St. · 04/08 07:15
DJ Chimerix Initiated at Outperform by Wedbush
Dow Jones · 03/31 12:09
DJ Chimerix Price Target Announced at $14.00/Share by Wedbush
Dow Jones · 03/31 12:09
DJ Chimerix Initiated at Buy by Jefferies
Dow Jones · 03/31 12:08
DJ Chimerix Price Target Announced at $21.00/Share by Jefferies
Dow Jones · 03/31 12:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMRX. Analyze the recent business situations of Chimerix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMRX stock price target is 15.00 with a high estimate of 21.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 39.22M
% Owned: 45.78%
Shares Outstanding: 85.68M
TypeInstitutionsShares
Increased
22
546.82K
New
20
738.02K
Decreased
34
1.41M
Sold Out
7
341.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Martha Demski
President/Chief Executive Officer/Director
Michelle Berrey
President/Chief Executive Officer/Director
Michael Sherman
Chief Financial Officer
Michael Andriole
Chief Executive Officer
W. Garrett Nichols
Senior Vice President/General Counsel
Michael Alrutz
Independent Director
Catherine Gilliss
Chief Accounting Officer
David Jakeman
Independent Director
Edward Greissing
Independent Director
Patrick Machado
Independent Director
Robert Meyer
Independent Director
Fred Middleton
Independent Director
C. Patrick Machado
Independent Director
Pratik Multani
Independent Director
Clarence Machado
No Data
About CMRX
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.